vs
Side-by-side financial comparison of NOVA LTD. (NVMI) and Bio-Techne (TECH). Click either name above to swap in a different company.
NOVA LTD. is the larger business by last-quarter revenue ($433.3M vs $311.4M, roughly 1.4× Bio-Techne). NOVA LTD. runs the higher net margin — 30.7% vs 16.4%, a 14.3% gap on every dollar of revenue.
Nova Ltd., formerly known as Nova Measuring Instruments, is a publicly traded company that provides advanced metrology solutions for semiconductor manufacturing. Founded in 1993, the company specializes in dimensional, materials, and chemical metrology technologies. Nova is listed on both the NASDAQ Global Market and on the Tel Aviv Stock Exchange under the ticker symbol NVMI.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
NVMI vs TECH — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $433.3M | $311.4M |
| Net Profit | $133.1M | $51.0M |
| Gross Margin | 57.6% | 66.9% |
| Operating Margin | 29.7% | 24.2% |
| Net Margin | 30.7% | 16.4% |
| Revenue YoY | — | -1.5% |
| Net Profit YoY | — | 126.0% |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | — | $295.9M | ||
| Q2 25 | $433.3M | $317.0M | ||
| Q1 25 | — | $316.2M | ||
| Q4 24 | — | $297.0M | ||
| Q3 24 | — | $289.5M | ||
| Q2 24 | — | $306.1M | ||
| Q1 24 | — | $303.4M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | — | $38.0M | ||
| Q2 25 | $133.1M | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | — | $33.6M | ||
| Q2 24 | — | $40.6M | ||
| Q1 24 | — | $49.1M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q2 25 | 57.6% | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | — | 18.4% | ||
| Q2 25 | 29.7% | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 15.0% | ||
| Q1 24 | — | 22.1% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | — | 12.8% | ||
| Q2 25 | 30.7% | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 11.6% | ||
| Q2 24 | — | 13.3% | ||
| Q1 24 | — | 16.2% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | — | $0.24 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $348.4M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $2.1B |
| Total Assets | $1.5B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | — | $172.9M | ||
| Q2 25 | $348.4M | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M | ||
| Q1 24 | — | $145.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | — | $2.0B | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.0B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | — | $2.5B | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $114.2M | — |
| Free Cash FlowOCF − Capex | $102.6M | — |
| FCF MarginFCF / Revenue | 23.7% | — |
| Capex IntensityCapex / Revenue | 2.7% | — |
| Cash ConversionOCF / Net Profit | 0.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q2 25 | $114.2M | $98.2M | ||
| Q1 25 | — | $41.1M | ||
| Q4 24 | — | $84.3M | ||
| Q3 24 | — | $63.9M | ||
| Q2 24 | — | $75.5M | ||
| Q1 24 | — | $81.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q2 25 | $102.6M | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q2 25 | 23.7% | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q2 25 | 2.7% | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 5.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NVMI
| Products | $351.8M | 81% |
| Services | $81.6M | 19% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
